Aptar Pharma Acquires Mod3 Pharma's Clinical Trial Materials Manufacturing Capabilities
July 15, 2025
Aptar Pharma has acquired the Phase 1 and 2 clinical trial materials manufacturing capabilities of Mod3 Pharma (formerly Enteris Biopharma) from SWK Holdings. The deal adds cGMP fill-and-finish, high-potency API suites and biologics capabilities at a Boonton, New Jersey facility to Aptar's drug delivery and early-stage development services to accelerate adoption of its delivery technologies.
- Buyers
- Aptar Pharma (AptarGroup, Inc.)
- Targets
- Mod3 Pharma (formerly Enteris Biopharma) - clinical trial materials manufacturing capabilities
- Sellers
- SWK Holdings
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Transaction Type
- Divestiture
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.